Lowering the criterion for impaired fasting glucose - Impact on disease prevalence and associated risk of diabetes and ischemic heart disease

被引:74
作者
Tai, ES
Goh, SY
Lee, JJM
Wong, MS
Heng, D
Hughes, K
Chew, SK
Cutter, J
Chew, W
Gu, K
Chia, KS
Tan, CE
机构
[1] Singapore Gen Hosp, Dept Endocrinol, Singapore 169608, Singapore
[2] Natl Univ Singapore, GIS Ctr Mol Epidemiol, Singapore 117548, Singapore
[3] Alexandra Hosp, Dept Med, Singapore, Singapore
[4] Minist Hlth, Epidemiol & Dis Control Div, Singapore, Singapore
[5] Natl Med Res Council, Clin Trials & Epidemiol Unit, Singapore, Singapore
[6] Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117548, Singapore
关键词
D O I
10.2337/diacare.27.7.1728
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To determine the effect of lowering the fasting plasma glucose (FPG) criterion for impaired fasting glucose (IFG) on the prevalence of IFG, the risks of diabetes, and cardio- vascular disease (CVD) associated with IFG. RESEARCH DESIGN AND METHODS - Three Studies were used: 1) the 1998 National Health Survey (NHS98), a randomly selected cross-sectional sample of 4,723 subjects; 2) the Singapore Impaired Glucose Tolerance (IGT) Follow-up Study, a cohort Study comprising 295 IGT and 292 normal glucose tolerance subjects (frequency matched for age, sex, and et. h. me group) followed up from 1992 to 2000, and 3) the Singapore CVD Cohort Study, comprising 5,920 subjects from three cross-sectional studies in whom the first ischemic heart disease (IHD) event was identified through linkage to registry databases. Risk of diabetes (Singapore IGT Follow-up study) was estimated using logistic regression adjusted for age, sex, and ethnicity. Risk of IHD (Singapore CVD cohort) was estimated using stratified (by study, from which data were derived) Cox's proportional hazards models adjusted for age, sex, and ethnicity. RESULTS - Lowering the criterion for diagnosing IFG to 5.6 mmol/l increased the prevalence of IFG from 9.5 to 32.3% in the NHS98. The tower cutoff identified more subjects at risk of diabetes and IHD, but the relative risk was lower than that for IGT. CONCLUSIONS - Greater efforts to identify those With IGT, or a group at similar risk of diabetes and CVD, may be a more efficient public health measure than lowering the FPG criterion for diagnosing IFG.
引用
收藏
页码:1728 / 1734
页数:7
相关论文
共 28 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371
[4]   Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[5]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]  
Cutter J, 2001, B WORLD HEALTH ORGAN, V79, P908
[8]   Lowering the criterion for impaired fasting glucose will not provide clinical benefit [J].
Davidson, MB ;
Landsman, PB ;
Alexander, CM .
DIABETES CARE, 2003, 26 (12) :3329-3330
[9]  
Gavin JR, 1999, DIABETES CARE, V22, pS5
[10]  
Genuth S, 2003, DIABETES CARE, V26, P3160